Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Published: Mar 15, 2021
March 15, 2021 11:00 UTC
Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for
the Company’s Lead Product Candidate Vicineum™
Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021
1
Marketing Authorization Application submitted in Europe with potential approval in early 2022
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full-year ended December 31, 2020. The Company’s lead program, Vicineum, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In February 2021, the Food and Drug Administration (FDA) accepted for filing the Company s Biologi
Press release content from Business Wire. The AP news staff was not involved in its creation.
Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
March 10, 2021 GMT
BURLINGAME, Calif. (BUSINESS WIRE) Mar 10, 2021
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today reported financial results for the year ending December 31, 2020 and announced objectives for 2021.
“We are proud of all the advances Humanigen made in 2020, not just as a company, but as a key player in the development of an effective treatment for hospitalized COVID-19 patients,” said Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen. “We were able to take lenzilumab from the context of preventing and treating cytokine storm in other therapeutic categories and adapt it at unpr
Global Phase 3 D-LIVR study enrollment completion planned in 2021
Peginterferon Lambda for HDV
Global Phase 3 LIMT-2 study initiation planned in 2021
Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies
U.S. commercial launch in January 2021
EMA decision expected in 2H21
Lambda for COVID-19
Lancet Respiratory Medicine (Feld et al, 2021)
Considering strategic options to advance program
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Positive Phase 2 PREVENT study published in
JCEM (Craig et al, 2021)
Corporate
Pro-forma cash, cash equivalents and investments of $176.2M, including $128.8M as of December 31, 2020 plus $47.4M from net PRV sale proceeds received in January 2021, expected to fund planned operations through Q4 2023
Fourth Quarter and Full Year 2020 Financial Results
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021
- Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021
- Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021
News provided by
Share this article
Share this article
PALO ALTO, Calif., March 9, 2021 /PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today reported financial results for fourth quarter and full year 2020 and provided a business update. In 2021, we plan to achieve important, value creating milestones in both of our HDV clinical programs, said David Cory, President and CEO of Eiger. We will complete enrollment of the Phase 3 D-LIVR study of Lonafarnib, the first and only oral agent in development